Creat Said Planning to Sell U.K. Plasma Firm to Shanghai RAAS

  • Biggest China healthcare company would gain overseas footprint
  • Creat acquired BPL earlier this year for 820 million pounds

China’s Creat Group Corp. plans to sell a British maker of blood plasma therapies to publicly-traded affiliate Shanghai RAAS Blood Products Co., according to people familiar with the matter.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.